New antimalarial compound discovered

Promising lead kills parasites in both humans and mosquitoes

New antimalarial compound discovered

150702-antimalarial.pngJulian Rayner
Genome sequencing revealed that mutations causing the greatest resistance cluster together.

A study published in Nature develops a chemical that is effective against the deadly Plasmodium falciparum parasite at several stages of its life cycle. The chemical, DDD107498, was found during a screen of University of Dundee's library of compounds for drug discovery. Genetic approaches identified the target of the compound, which is a part of the parasite's biology that has not been attacked by previous drugs. Researchers therefore believe it has great potential to work against current drug-resistant parasites.

"The publication describes the discovery and profiling of this exciting new compound. It reveals that DDD107498 has the potential to treat malaria with a single dose, prevent the spread of malaria from infected people, and protect a person from developing the disease in the first place."

Professor Ian Gilbert, Head of Chemistry at the Drug Discovery University of Dundee, who led the team that discovered the compound

"There is still some way to go before the compound can be given to patients. However, we are very excited by the progress that we have made."

The compound was identified through a collaboration between the University of Dundee's Drug Discovery Unit (DDU) and Medicines for Malaria Venture (MMV), working with a team from the Wellcome Trust Sanger Institute.

To learn how the compound works, Dr Marcus Lee from Columbia University College of Physicians and Surgeons, who joins the Sanger Institute Malaria Programme faculty this month, developed malaria parasites in the lab that were resistant to DDD107498. This was done by growing malaria parasites in the lab and gradually increasing the dose of the compound that they were exposed to.

Researchers at the Sanger Institute then analysed the genomes of the resistant parasites and compared them with the genomes of drug sensitive lines to find out which genes had changed to confer resistance. The gene PfeEF2 was singled out in this comparison, which is involved in how the parasite synthesises new proteins.

New antimalarial drugs are needed urgently as emerging strains in South Asia are now resistant to artemisinin, the most effective drug currently available. Researchers fear that this resistance may develop in Africa or spread to Africa, where this drug is widely used.

"Drug resistance is one of the critical problems facing malaria control, and is a problem that we are deeply interested in. This exciting compound targets a completely new pathway, giving us hope that it will offer a different avenue of attack to current antimalarial drugs."

Dr Julian Rayner, a senior author from the Malaria Programme at the Sanger Institute

"Our partnership with MMV was critical to the progress of this compound. Dr Paul Willis at MMV and Sir Simon Campbell, a mentor from MMV's Expert Scientific Advisory Committee, gave invaluable input to the project. We have extensively profiled the compound, investigating its properties to understand how it works; this could not have been done without MMV's scientific input and support of its network of partners around the world."

Professor Ian Gilbert

Notes to Editors
  • A novel multiple-stage antimalarial agent that inhibits protein synthesis.

    Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R et al.

    Nature 2015;522;7556;315-20

About the topic

The World Health Organisation reports 200 million clinical cases of malaria in 2013, with 584,000 people dying from the disease. Most of these deaths were children under the age of 5 and pregnant women.

The University of Dundee team has been working with MMV since 2009 to identify potential new treatments for malaria. The project was initiated by testing a collection of around 4,700 compounds at the University of Dundee Drug Discovery Unit to see if any would kill the malaria parasite. From this screening, the chemical starting point was identified and then optimised through cycles of design, preparation and testing, by a team of chemists and biologists.

In October 2013, MMV selected DDD107498 to enter preclinical development following the recommendation of its Expert Scientific Advisory Committee. Since then, with MMV's leadership, large quantities of the compound have been produced and it is undergoing further safety testing with a view to entering human clinical trials within the next year.

In a critical next step in the progression of DDD107498, Merck Serono has recently obtained the right to develop and, if successful, commercialize the compound, with the input of MMV's expertise in the field of malaria drug development and access and delivery in malaria-endemic countries.


This work was supported by grants from Medicines for Malaria Venture, the Wellcome Trust 100476, 091625 and 098051, the Bill and Melinda Gates Foundation OPP1043501, the National Institutes of Health, R01 AI103058, and the European Union (EVIMalaR). Drug Discovery Unit infrastructure was supported by the European Regional Development Fund 2007-2013 and UK Research Partnership Investment Fund awards.

Participating Centres

A full list of participating centres can be found on the paper.

Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0) 7748 379849

Recent News

Salmonella responsible for bloodstream infections in central Africa resistant to nearly all drugs
Strain of dangerous pathogen shown to have developed resistance to last-line-of-defence drug
Babies' gut bacteria affected by delivery method, Baby Biome project shows
Vaginal delivery promotes mother's gut bacteria in baby's gut
500,000 whole human genomes will be a game-changer for research into human diseases
Following on from a successful pilot at the Sanger Institute, we are leading a project to sequence the genomes of all UK Biobank volunteers to power the next wave of genetic and health research